# NCT06670196 (NCT06670196)

> A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan (SKB264) plus osimertinib
- Indication: first-line EGFR-mutated locally advanced or metastatic non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06670196
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: SKB264; Osimertinib
- Enrollment: 420
- Primary outcome: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on NCT06670196 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06670196
